NEW YORK CITY, NY / ACCESS Newswire / February 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...

Sigma has had a busy day. It's unveiled a new visual identity for its brand, alongside announcements of a new mirrorless ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.

Teva Pharmaceuticals (TEVA), and Sanofi (SNY) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug, a human IgG1-2 ...

The increasing prevalence of chronic conditions like cardiovascular disease is driving the demand for transmucosal drugs. Key factors contributing to the transmucosal drugs market's growth from ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Teva Pharmaceutical Indus 30-Day Option Volume & Interest Snapshot Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its ...

today announced the award of a new contract with Teva Pharmaceutical Industries Ltd. (Teva), to install the SaverOne System across its entire fleet of 50 pharmaceutical delivery trucks.

Earnings per share (EPS) missed analyst estimates significantly. Looking ahead, revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the ...

Teva Pharmaceutical (NYSE:TEVA) shares snapped six straight sessions of losses, as the stock closed 0.88% higher at $17.21 on Wednesday. The company lost over 20% in the preceding six sessions.